A Phase 1 Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs CDX 1140 (Primary)
  • Indications Bladder cancer; Breast cancer; Cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 30 Nov 2017 Status changed from not yet recruiting to recruiting, according to a Celldex Therapeutics media release.
    • 07 Nov 2017 According to Celldex Therapeutics media release, this study is anticipated to open to enrollment by year-end 2017.
    • 31 Oct 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top